Likelihood of Approval and Phase Transition Success Rate Model – Calquence in Coronavirus Disease 2019 (COVID-19)
Powered by ![]()
Unlock hidden opportunities in the LoA industry
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model – Calquence in Coronavirus Disease 2019 (COVID-19) report and make more profitable business decisions.
This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.


Calquence in Coronavirus Disease 2019 (COVID-19) Drug Details:
Acalabrutinib maleate (Calquence) is an anti-neoplastic agent. It is formulated as hard gelatin capsules, tablets, coated tablets and film coated tablets for oral route of administration. Calquence is indicated for the treatment of of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy, for the treatment of patients with chronic lymphocytic leukaemia (CLL) or small lymphocytic leukaemia (SLL) either as initial therapy or subsequent therapy.. and also in combination with obinutuzumab or as a monotherapy is indicated for the treatment of relapsed or refractory chronic lymphocytic leukemia. Calquence as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy.Acalabrutinib is under development for the treatment of peanut food allergy, recurrent or refractory central nervous system lymphoma (CNSL), anti-MAG mediated neuropathy, multiple myeloma, hairy cell leukemia, graft-versus-host disease, primary, secondary central nervous system lymphoma and secondary diffuse large B-cell lymphoma (DLBCL), first line diffuse large B-cell lymphoma, relapsed or refractory small lymphocytic lymphoma, refractory or relapsed or untreated mantle cell lymphoma, marginal zone B-cell lymphoma, Waldenstrom macroglobulinemia, follicular lymphoma, marginal zone lymphoma, B-cell lymphoproliferative disorder, splenic marginal zone lymphoma nodal marginal zone lymphoma and extranodal marginal zone lymphoma, epithelial ovarian cancer, follicular lymphoma and relapsed, refractory and untreated chronic lymphocytic leukemia, relapsed or refractory mantle cell lymphoma, primary mediastinal [thymic] large B-cell lymphoma (PMBCL) and other B-cell malignancies, coronavirus disease 2019 (COVID-19), primary and secondary central nervous system lymphoma. It was also under development for relapsed and refractory multiple myeloma, fallopian tube cancer, peritoneal cancer, metastatic bladder cancer, metastatic pancreatic cancer, metastatic squamous lung adenocarcinoma, rheumatoid arthritis, metastatic urothelial carcinoma, recurrent, metastatic, recurrent glioblastoma multiforme, unresectable head and neck squamous cell carcinoma coronavirus disease 2019 (COVID-19), pneumonia and cytokine storm.
Report Coverage
The data is segmented by drug name per indication and shows the current likelihood of approval for the drug compared to the indication benchmark and the industry benchmark.
The Likelihood of Approval data is updated regularly based on events that take place which impact the clinical development process and regulatory considerations. GlobalData’s proprietary machine learning models consider these events in real time, to produce quantitative changes to the LOA and PTSR along with qualitative reasoning why the likelihood of approval has changed.
| Quick View – Calquence LOA Data | |||||
| Report Segments |
|
||||
| Drug Name |
|
||||
| Administration Pathway |
|
||||
| Therapeutic Areas |
|
||||
| Key Manufacturers |
|
||||
| Drug Development Status |
|
||||
Reasons to Buy
- Precise Likelihood of Approval and Phase Transition Success Rates: Our machine learning and proprietary models provide accurate predictions, helping you gauge the potential success of a drug in the regulatory process.
- Competitive Strategy Planning: Access information on LOA and PTSR for competitors’ drugs, allowing you to plan your clinical development, commercialisation and marketing strategies
- Event-driven Updates: Track event-driven changes in LOA and PTSR benchmarked against indication LOA/PTSR. Get the latest insights to adapt your strategies promptly!
- Well-informed Investment Decisions: This data helps you navigate the dynamic landscape of drug development and regulatory considerations.
Scope
- Drug Details: Drug name, Drug type, Intervention type
- Administration Pathway
- Therapeutic Areas
- Key Manufacturers
- Drug Development Status
This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Related reports
View more Pharmaceuticals reports